Foundayo Weight Loss Pill

Foundayo (orforglipron) is an FDA-approved oral GLP-1 weight loss pill taken once daily for chronic weight management in adults with obesity, or in some adults who are overweight and have weight-related medical problems. It is used together with a reduced-calorie diet and increased physical activity to help reduce excess body weight and maintain weight loss long term.

Foundayo contains orforglipron, a small-molecule, non-peptide GLP-1 receptor agonist. Unlike some other oral GLP-1 medicines, Foundayo can be taken at any time of day, with or without food, and without water restrictions, which may make it a more convenient option for some patients.

Foundayo should not be used with other GLP-1 receptor agonist medicines.

The FDA approved Foundayo for weight management on April 1, 2026, by Eli Lilly.

Foundayo was effective for weight loss in a 72-week clinical trial (Trial 1) of adults with obesity or overweight without diabetes, with greater weight loss seen at higher doses.

In clinical Trial 1 (NCT05869903), the average weight loss for Foundayo was 7.4% to 11.1% (16.8 lbs to 25.2 lbs) at 72 weeks compared to 2.1% (4.8 lbs) with placebo. These results show that Foundayo supports long-term weight loss and that higher daily doses were associated with greater average weight reduction.

Foundayo weight loss results (Trial 1)

Key weight loss takeaways

• Weight loss increased as the Foundayo dose increased.
• Foundayo 17.2 mg produced the greatest average weight loss: 11.1%, or about 25.2 pounds.
• Across the doses studied, average weight loss with Foundayo ranged from 16.8 to 25.2 pounds.

For more detailed results, see "How much weight loss was seen with Foundayo in 72-week clinical trials?"

Foundayo weight loss results (Phase 3 ATTAIN-1 trial)

In Lilly’s Phase 3 ATTAIN-1 trial, adults with obesity who received the highest dose of orforglipron (36mg) for 72 weeks lost an average of 27.3 pounds (12.4%), compared with 2.2 pounds (0.9%) with the placebo. The 36 mg orforglipron capsules used in investigational trials are equivalent in dose to the FDA-approved Foundayo 17.2 mg tablets

The study also found improvements in several cardiometabolic risk markers, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.

Foundayo is an oral GLP-1 receptor agonist that helps with weight loss by mimicking GLP-1, a natural hormone released after eating. GLP-1 helps regulate appetite, food intake, and digestion. Foundayo works by reducing hunger, increasing feelings of fullness, and slowing stomach emptying, which can help people eat less and feel satisfied longer.

Unlike some other oral GLP-1 medications, Foundayo can be taken once daily at any time of day without food or water restrictions. This may make it more convenient than oral semaglutide, which must be taken on an empty stomach with a small amount of water and requires a waiting period before food, drink, or other medicines

• Take Foundayo exactly as prescribed.
• Use it together with a reduced-calorie diet and increased physical activity.
• Take a Foundayo pill by mouth once daily, with or without food.
• Swallow tablets whole. Do not break, crush, or chew them.
• Your dose is increased gradually over time to help your body adjust to the medicine and improve tolerability.
• If you miss a dose, take it as soon as possible. Do not take 2 doses in the same day.
• Do not take more than 1 tablet per day.
• If you miss treatment for 7 or more days in a row, contact your healthcare provider before restarting.
• If you take too much, call your healthcare provider, Poison Help (1-800-222-1222), or go to the nearest emergency room.

Foundayo Dose Schedule

Foundayo is supplied as oral tablets in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg strengths.

Foundayo has a boxed warning for the increased risk of thyroid C-Cell tumors.

• Possible thyroid tumors, including thyroid cancer. Tell your healthcare provider right away if you notice a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In rodent studies, medicines like Foundayo caused thyroid tumors, including thyroid cancer. It is not known whether Foundayo causes thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.
• Do not take Foundayo if you or anyone in your family has ever had medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Do not take Foundayo if:

• You have a personal or family history of MTC or in patients with MEN 2
• You have severe liver impairment (Child-Pugh Class C)
• Known serious hypersensitivity to the active ingredient orforglipron or any of the inactive ingredients found in the medicine.

Common side effects

The most common Foundayo side effects are nausea, stomach (abdominal) pain, heartburn, constipation, headache, gas, diarrhea, bloating, hair loss, vomiting, tiredness, indigestion, and belching.

Serious side effects

Also, see “Boxed Warnings?”

This medicine may cause serious side effects, including:

• Inflammation of the pancreas (pancreatitis). Stop taking this medicine and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.
• Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo Tell your healthcare provider if you have stomach problems that are severe or will not go away.
• Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.
• Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as insulin or sulfonylurea. Signs and symptoms of low blood sugar may include:
• Serious allergic reactions. Stop taking this medicine and get medical help right away if you have any symptoms of a serious allergic reaction including:
• Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with this medicine.
• Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems which may include:
• Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayomay increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking this medicine before you are scheduled to have surgery or other procedures.

Talk to your healthcare provider if you have any side effects that bothers you or that does not go away. These are not all the possible side effects of FOUNDAYO. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Foundayo will be available through LillyDirect, with prices starting at $25 per month for eligible commercially insured patients, and self-pay pricing starting at $149 per month for the lowest dose. Lilly also said some eligible Medicare Part D beneficiaries may be able to access Foundayo for $50 per month beginning as soon as July 1, 2026.

Availability and pricing programs can change. Coverage, eligibility rules, and retail pharmacy access should be verified before prescribing or dispensing.

For more details, see "How much does Foundayo cost?"

When comparing Foundayo (orforglipron) to existing oral GLP-1 therapies like Wegovy (semaglutide), the primary distinction lies in their molecular structure and administration requirements.

Why Foundayo Offers More Flexibility

Unlike traditional GLP-1 agonists, Foundayo is a small-molecule, nonpeptide medication. This structural advantage leads to several patient benefits:

• Enhanced Bioavailability: Its small-molecule design allows the body to absorb the medication more efficiently through the digestive tract.
• No Fasting Required: You can take Foundayo at any time of day, regardless of food or liquid intake.

The Challenges of Peptide-Based Medications

In contrast, oral Wegovy (semaglutide) is a peptide-based molecule. Because peptides are large and fragile, they are easily broken down by stomach acid before they can reach the bloodstream. To combat this, oral semaglutide requires:

• Strict Dosing Schedules: It must be taken on an empty stomach with no more than 4 ounces of plain water.
• Wait Times: Patients must wait at least 30 minutes before eating or drinking anything else.
• Chemical Enhancers: It relies on salcaprozate sodium (SNAC), an absorption enhancer, to protect the peptide and facilitate its passage into the blood.

• Tell your healthcare provider about all medical conditions and all medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.
• Tell your provider if you have or have had pancreas problems, kidney problems, severe liver problems, severe stomach problems such as gastroparesis, or a history of diabetic retinopathy.
• Tell your provider if you are scheduled for surgery or another procedure using anesthesia or deep sedation.

Pregnancy

Tell your healthcare provider if you are pregnant or plan to become pregnant. Foundayo may harm your unborn baby. Tell your healthcare provider if you become pregnant while taking this medicine.

• Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health and that of your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
• Birth control pills by mouth may not work as well while taking this medicine. If you take birth control pills by mouth, your healthcare provider may recommend another type of birth control for 30 days after you start Foundayo and for 30 days after each increase in your dose of Foundayo. Talk to your healthcare provider about birth control methods that may be right for you while using this medicine.

Breastfeeding

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Foundayo. Talk to your healthcare provider about the best way to feed your baby while using this medicine.

Tell your healthcare professional about all medications you take, including prescription and over-the-counter medicines, vitamins, and herbal products.

• Strong CYP3A4 inhibitors can increase Foundayo levels and side effects. Limit Foundayo to 9 mg once daily and avoid use with strong CYP3A4 inhibitors that also inhibit OATP1B.
• Strong CYP3A4 inducers can lower Foundayo levels and make it less effective. Avoid using them with Foundayo.
• Moderate CYP3A4 inducers may also lower Foundayo levels. Monitor response and adjust the Foundayo dose if needed.
• Foundayo can increase simvastatin exposure. Do not exceed simvastatin 20 mg once daily.
• Foundayo may increase the risk of hypoglycemia when used with insulin or sulfonylureas. Consider lowering the dose of those drugs when starting Foundayo
• Foundayo delays gastric emptying, which may affect the absorption of oral medications.
• Patients taking oral hormonal contraceptives should use a non-oral or barrier contraceptive method for 30 days after starting Foundayo and for 30 days after each dose increase.

Other drugs may interact with Foundayo, not all possible drug interactions are listed here.

• Store at room temperature between 68°F to 77°F (20°C to 25°C).
• Protect from light by keeping the tablets in the original bottle and carton and replacing the cap after opening.
• If the carton is no longer available, keep the bottle away from light.
• Keep out of the reach of children.

Store between 68°F to 77°F (20°C to 25°C).

Foundayo tablets are sensitive to light. Protect tablets from light by keeping it in the original bottle and carton and replacing the cap each time after opening.

If you no longer have the carton, store the bottle away from light.

Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA

Active ingredient: orforglipron

Inactive ingredients: Copovidone, crospovidone, magnesium stearate, microcrystalline cellulose, and sodium carbonate anhydrous.

The film coating contains: polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. The film coating of the 0.8 mg and 9 mg tablets also contains ferric oxide red and ferric oxide yellow, 2.5 mg and 14.5 mg tablets also contain ferric oxide yellow, and 5.5 mg and 17.2 mg tablets also contain ferrosoferric oxide and ferric oxide red.